GSK’s reduced dependence on "white pills" makes pharma performance hard to swallow
This article was originally published in Scrip
The "returns-based" reengineering of GlaxoSmithKline's business continues to take its toll on the company's bottom line as the company reported its full year results for 2010. Legal charges and restructuring costs took nearly 75% out of the earnings per share across the whole company, and pharmaceutical revenues were substantially down in the US and European markets.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.